DXCM Stock Analysis: Buy, Sell, or Hold?
DXCM - DexCom, Inc.
$57.89
-0.68 (-1.16%)
▼
5d:
-4.96%
30d:
-5.93%
90d:
-11.05%
BUY
HIGH Confidence
Analysis Updated: May 14, 2026 12:00 AM ET
Earnings: Apr 30, 2026
0d
Smart Money Distribution
DXCM is up 4.9% this week, but smart money is buying puts. Top strike: $70 2026-06-18 with 5,212 OI. Put ratio: 62% View Scanner →
Strength: 3.6/10
Get Alerted When DXCM Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
2 traders called DXCM this week
55% bullish • 5 bearish
55% bullish • 5 bearish
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
✅ BUY SIGNAL: DXCM appears deeply undervalued. Market expects -7.8% annual earnings decline despite 92% recent earnings growth. Contrarian opportunity at discount to historical valuation.
✅ BUY SIGNAL: DXCM appears deeply undervalued. Market expects -7.8% annual earnings decline despite 92% recent earnings growth. Contrarian opportunity at discount to historical valuation.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$125.85
Based on 11.1% avg growth
INTRINSIC VALUE TODAY
$78.14
25.9% Margin of Safety
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 24.5x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: DXCM is currently trading at $57.89, which is considered oversold relative to its 30-day fair value range of $59.53 to $63.76. From a valuation perspective, the stock is trading at a discount (Forward PE: 19.2) compared to its historical average (24.5). Remarkably, the market is currently pricing in an annual earnings decline of 7.8% over the next few years. This pessimistic expectation contrasts with the company's recent 92.2% earnings growth, suggesting potential undervaluation if the company simply maintains stability.
Technical Outlook: Technically, DXCM is in a strong downtrend. The price is currently testing key support at $57.66. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: The stock shows a mixed technical setup (45/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $83.28 (+42.2%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, DXCM is in a strong downtrend. The price is currently testing key support at $57.66. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: The stock shows a mixed technical setup (45/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $83.28 (+42.2%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$59.53 -
$63.76
Company Quality Score
60/100
(BUY)
Volume Confirmation
HIGH
Confidence Score
79.5%
All Signals
- BULLISH: Price oversold vs 30-day range
- NEUTRAL: Mixed technical signals (45/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 42.2% below Wall St target ($83.28)
Trading Range Analysis
30-Day Trading Range
$59.53 -
$63.76
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$57.66
Resistance Level
$62.85
Current Trend
Strong Downtrend
Technical data as of
May 14, 2026
Fundamental Context
Forward P/E (Next Year Est.)
19.20
Wall Street Target
$83.28
(+42.2%)
Revenue Growth (YoY)
15.0%
Earnings Growth (YoY)
92.2%
Profit Margin
19.3%
Valuation Discount vs History
-7.8% cheaper
PE vs Historical
19.2 vs 24.5
CHEAP
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-7.8%
(market-implied from PE analysis)
1-Year Target
$54.00
(-8%)
2-Year Target
$49.79
(-15%)
3-Year Target
$45.91
(-22%)
3-Yr Target (if PE normalizes)
(PE: 19→25)
$58.57
(0%)
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 22.0, Growth: 18.2%)
$111.06
(+90%)
Base:
(SPY PE: 19.2, Growth: 18.2%)
$96.76
(+65%)
Bear:
(PE: 16.3, Growth: 18.2%)
$82.25
(+40%)
📈
Valuation based on Current Earnings
RECOVERY PLAY: Stock looks expensive now (26x PE), but valuation improves significantly next year (19x PE) as earnings recover.
Trailing PE: 26.24 | Current EPS (TTM): $2.33
Bull Case
$88.04
(+50%)
Analyst growth 30.9%, PE expands to 28.9
Base Case
$80.04
(+37%)
Market implied 30.9%, PE stable at 26.2
Bear Case
$41.58
(-29%)
Severe decline -20.0%, PE contracts to 22.3
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
💡
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 19.2 to 24.5
Stabilization Target:
$74.73
(+27.6%)
PE Expansion Potential:
+27.6%
Share & Embed Analysis
Last updated: May 14, 2026 3:40 PM ET
Data refreshes hourly during market hours. Next update: 4:40 PM
Data refreshes hourly during market hours. Next update: 4:40 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is DXCM showing a specific setup today?
Insider Activity (6 Months)
3
Buys
6
Sells
Net
INSIDERS SELLING
Recent Transactions
Michael Jon Brown
SELL
1700 shares
2026-04-15
Ro Khanna
SELL
2026-03-30
Ro Khanna
SELL
2026-03-23
Top Rated Medical Devices Stocks
Top-rated stocks in Medical Devices by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
BSX
Boston Scientific Corp |
STRONG BUY
34 analysts |
$85 | 55 HOLD |
|
SYK
Stryker Corporation |
BUY
32 analysts |
$392 | 62 BUY |
|
MDT
Medtronic PLC |
BUY
32 analysts |
$108 | 62 BUY |
|
ABT
Abbott Laboratories |
BUY
28 analysts |
$119 | 53 HOLD |
|
PODD
Insulet Corporation |
STRONG BUY
23 analysts |
$250 | 58 HOLD |
Advanced DXCM Option Strategies
Professional options setups generated by AI based on today's DXCM price and gamma walls.
